Definium Therapeutics
DFTX
208 hedge funds and large institutions have $909M invested in Definium Therapeutics in 2025 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 92 increasing their positions, 31 reducing their positions, and 30 closing their positions.
197% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 31
117% more call options, than puts
Call options by funds: $23.4M | Put options by funds: $10.8M
94% more capital invested
Capital invested by funds: $469M → $909M (+$440M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
67% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 30
16.66% more ownership
Funds ownership: 52.23% → 68.89% (+17%)
7% more funds holding
Funds holding: 195 → 208 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$61.9M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$42.4M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$29.5M |
| 4 |
BlackRock
New York
|
+$28.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$15.2M |
| 2 |
Blackstone Inc
New York
|
-$8.87M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$7.08M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$4.26M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.6M |
DFTX Hedge Fund Activity: Q4 2025 in Review
208 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q4 2025, worth a combined $909M — up 94% from $469M a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new DFTX positions and 30 closed out — a net gain of 20 holders — while 92 added to existing stakes and 31 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $61.9M. The largest seller was Commodore Capital, cutting an estimated $15.2M.
- 208 institutional investors held Definium Therapeutics (DFTX) as of Q4 2025, up from 195 in Q3 2025.
- Funds reported $909M of Definium Therapeutics stock for Q4 2025, up 94% quarter-over-quarter.
- 50 funds opened new Definium Therapeutics positions in Q4 2025 and 30 closed out, a net change of +20 holders.
- The largest Definium Therapeutics buyer in Q4 2025 was Avoro Capital Advisors, an estimated $61.9M added.
- The largest Definium Therapeutics seller in Q4 2025 was Commodore Capital, an estimated $15.2M sold.
Based on aggregated 13F filings for Q4 2025.